House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Endocrinology

Type 1 diabetes in adults: diagnosis and management

NICE · 2022 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This focused NICE NG17 summary covers adult type 1 diabetes diagnosis, education, glucose monitoring, injection principles and hypoglycaemia safety. It emphasizes individualized targets and access to continuous glucose monitoring. The captured guideline contains older retained recommendations alongside updated advice and a current insulin-supply notice; detailed emergencies, pregnancy and device eligibility require their dedicated pathways.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Classify diabetes carefully

  • Make an initial clinical diagnosis in an adult presenting with hyperglycaemia, using features such as ketosis, weight loss and autoimmune history. Age or BMI alone must neither diagnose nor exclude type 1 diabetes; revisit the classification if uncertainty remains. [1]
  • Measure diabetes-specific autoantibodies at initial diagnosis, when false negatives are least likely. Testing 2 different antibodies reduces the false-negative rate. Do not routinely measure C-peptide solely to confirm the initial diagnosis. [1]
  • If antibodies are negative and classification remains uncertain, consider non-fasting serum C‑peptide with a paired glucose. C-peptide is also useful for revisiting a doubtful classification later, with greater discriminatory value as time from diagnosis increases. [1]

Build self-management skills and an individual plan

  • Agree an individual care plan and review it annually, adapting to preferences, circumstances and findings. Include insulin adjustment, self-monitoring, hypoglycaemia prevention, pregnancy planning, complication review and how to contact the diabetes team. [1]
  • Offer structured education of proven benefit, such as DAFNE, usually 6–12 months after diagnosis; offer it later if not previously received. Provide an equal-standard alternative when group education is unsuitable or unwanted. Information and support begin from diagnosis, rather than waiting for the course. [1]

Use individualized targets and supported monitoring

  • Check HbA1c every 3–6 months, more often if control is changing rapidly. The guideline supports an HbA1c aim of 48 mmol/mol (6.5%) or lower, individualized for daily activities, comorbidities and hypoglycaemia history; achieving it must not cause problematic hypoglycaemia. [1]
  • Offer a choice of real-time or intermittently scanned CGM according to preferences, needs, personal characteristics and available device functionality. Provide CGM through a team experienced in its use, supporting the person to manage their diabetes. [1]
  • CGM users still need capillary testing to check device accuracy and as backup when readings change rapidly or the device fails. Supply sufficient strips. Offer capillary monitoring when CGM cannot be used or is declined. [1]
  • For adults relying on capillary monitoring, advise at least 4 measurements daily, including before meals and bed. Additional testing is needed according to illness, activity, hypoglycaemia, driving or other individual risks; the routine minimum is not a maximum. [1]
  • NICE’s adult plasma-glucose aims are 5–7 mmol/L on waking and 4–7 mmol/L before other meals. If measuring after meals, aim for 5–9 mmol/L at least 90 minutes after eating. Agree bedtime targets individually; pregnancy follows a separate target pathway. [1]

Preserve basal–bolus treatment and check current products

  • For injection therapy, offer a multiple-daily-injection basal–bolus regimen with training. Do not start newly diagnosed adults on basal-only, bolus-only or twice-daily mixed insulin as the initial regimen. [1]
  • The captured UK guideline flags the planned discontinuation of insulin detemir, with anticipated supply ending in December 2026, and directs clinicians to alternative-basal-insulin guidance. The older detemir preference should not be used without checking current availability and a planned transition. [1]

Prevent severe hypoglycaemia and escalate emergencies

  • Assess hypoglycaemia awareness annually using the Gold or Clarke score. For impaired awareness, reinforce structured education, review insulin doses and consider pump or real-time CGM options; refer to a specialist centre when recurrent severe episodes persist despite these measures. [1]
  • Treat hypoglycaemic symptoms with fast-acting glucose when swallowing is safe. Reduced consciousness makes oral treatment unsafe: the guideline describes intramuscular glucagon by a trained relative or friend, or intravenous glucose by a professional skilled in venous access. [1]
  • After treatment of hypoglycaemia with reduced consciousness, check response at 10 minutes and give intravenous glucose if consciousness is not improving significantly. Once safe, give oral carbohydrate and continue observation with awareness that hypoglycaemia can recur. [1]
  • For increasing or problematic hypoglycaemia, review insulin distribution, meals, activity and alcohol, injection technique and sites, gastroparesis, altered insulin sensitivity including renal failure, and mental-health or self-management difficulties. [1]
  • Consider blood or urine ketone monitoring within sick-day rules. In emergency care, consider blood ketones when DKA is suspected, or when illness causes uncontrolled diabetes with positive urine ketones. DKA needs a formal, continuously monitored treatment pathway with frequent reassessment. [1]

Include oral health in continuing care

  • Discuss the increased risk of periodontitis at annual review and encourage regular oral-health reviews. Treat diagnosed periodontitis through the dental team according to individual oral-health needs; management can improve glucose control. [1]

Limitations and use

  • Selected adult diagnosis and self-management recommendations are summarized. This is not a complete insulin prescription, pump or hybrid-closed-loop eligibility pathway, pregnancy plan, inpatient regimen, or microvascular and cardiovascular complication protocol.
  • Exact hypoglycaemia drug doses and carbohydrate quantities are not supplied. DKA fluid, insulin, potassium and stopping rules are not reconstructed from the older retained NICE text; use a current dedicated emergency protocol.
  • The detemir supply notice concerns the captured UK source and is not a verified Indian product-availability statement. Treatment changes require current product guidance and an individualized plan.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Type 1 diabetes in adults: diagnosis and management

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
26 August 2015
Publisher’s latest update
17 August 2022
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Classify diabetes carefully
  • Build self-management skills and an individual plan
  • Use individualized targets and supported monitoring
  • Preserve basal–bolus treatment and check current products
  • Prevent severe hypoglycaemia and escalate emergencies
  • Include oral health in continuing care
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House